Helix BioPharma Corp. announces management changes

    AURORA, ON, Nov. 15 /CNW/ - Helix BioPharma Corp. (TSX, FSE: "HBP") today
announced position changes for Dr. Donald Segal and John Docherty. Effective
immediately, the joint role of Chief Executive Officer and President formerly
held by Dr. Segal will be separated whereby Dr. Segal will remain the
Company's Chief Executive Officer and Mr. Docherty will assume the role of
    "These changes are being made as we strive to expand our corporate
initiatives, primarily in the U.S.A.," said Dr. Segal. "Moving forward, I am
pleased to have John take on added responsibilities so that I may increasingly
focus my time on growing our business by developing new financial, partnering
and other strategic initiatives for the Company. John will concentrate on
enhancing our public profile, overseeing our advancing clinical programs and
managing our related day to day operations."
    Dr. Segal and Mr. Docherty have a history of proven leadership with the
Company. Dr. Segal is a founding partner, serves on the board of directors and
had been Chief Executive Officer and President since 2004. Mr. Docherty joined
the Company in 1999 with degrees in toxicology and pharmacology and a
comprehensive background in pharmaceutical product and corporate development.
At Helix, Mr. Docherty has been instrumental in developing the Company's lead
product candidate, Topical Interferon Alpha-2b, in addition to supporting the
Company's growing investor and media relations initiatives. Previously, Mr.
Docherty served as Vice President, Corporate Development since 2002.

    About Helix BioPharma Corp.

    Helix BioPharma Corp. is a biopharmaceutical company specializing in the
field of cancer therapy. The Company is actively developing innovative
products for the prevention and treatment of cancer based on its proprietary
technologies. Helix's product development initiatives include its Topical
Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed
on the TSX under the symbol "HBP".

    The Toronto and Frankfurt Stock Exchanges have not reviewed and do not
accept responsibility for the adequacy or accuracy of the content of this News
Release. This News Release contains certain forward-looking statements and
information regarding Helix's strategic, financing and product development
initiatives. Forward-looking statements and information can be identified by
the use of forward-looking terminology such as "will", "strive to expand",
"enhancing", "advancing", "growing", "developing" and "initiatives". Helix's
actual results could differ materially from those anticipated in these
forward-looking statements and information as a result of numerous risks,
uncertainties and assumptions, including without limitation, Helix's need for
additional capital in the near term and in future, which may not be available
on acceptable terms or at all; uncertainty whether Helix's strategic and
financing initiatives in the U.S.A. will be successful; and uncertainty
whether Topical Interferon Alpha-2b, L-DOS47, or any other product will be
developed and marketed successfully as a drug or at all. See a description of
other risks and uncertainties affecting Helix and its business, as contained
in Helix's latest Annual Information Form and other filings with the Canadian
Securities Regulatory Authorities at www.sedar.com, any of which could cause
actual results to vary materially from current results or Helix's anticipated
future results. Forward-looking statements and information are based on the
assumptions, beliefs, opinions and expectations of Helix's management at the
time they are made, and Helix does not assume any obligation, except as
required by law, to update any forward-looking statement or information should
those assumptions, beliefs, opinions or expectations, or other circumstances

For further information:

For further information: Investor Relations, Christina Bessant, The
Equicom Group Inc., Tel: (416) 815-0700 ext. 269, (800) 385-5451, Fax: (416)
815-0080, Email: cbessant@equicomgroup.com; Media Relations, David Schull,
Russo Partners LLC, Tel: (212) 845-4271, Fax: (212) 845-4260, Email:
David.Schull@russopartnersllc.com, www.russopartnersllc.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890